Top 5 (Ranked by Importance)
Index | : | 1 |
Title | : | Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion |
Journal | : | Cancer Research, 67(1):309–317 |
Authors | : | Cheng PNM, et al. |
Year | : | 2007 |
Index | : | 2 |
Title | : | Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma |
Journal | : | Journal of Hematology & Oncology, 11:68 |
Authors | : | De Santo C, Cheng P, et al. |
Year | : | 2018 |
Index | : | 3-1 |
Title | : | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma |
Journal | : | Investigational New Drugs, 31(1):99–107 |
Authors | : | Yau T, Cheng PN, et al. |
Year | : | 2013 |
Index | : | 3-2 |
Title | : | Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma |
Journal | : | Investigational New Drugs, 33(2):496–504 |
Authors | : | Yau T, Cheng PN, et al. |
Year | : | 2015 |
Index | : | 4 |
Title | : | Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target |
Journal | : | Blood, 125(15):2386–2396 |
Authors | : | Mussai F, …, Cheng P, et al. |
Year | : | 2015 |
Index | : | 5 |
Title | : | Macrophage PTEN regulates expression and secretion of Arginase I modulating innate and adaptive immune responses |
Journal | : | The Journal of Immunology, 193(4):1717–1727 |
Authors | : | Sahin E, …, Cheng P, et al. |
Year | : | 2014 |
Others (Ranked by Year of Publication)
Index | : | 6 |
Title | : | Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma |
Journal | : | Cancer letters, 224(1):67–80 |
Authors | : | Cheng PNM, et al. |
Year | : | 2005 |
Index | : | 7 |
Title | : | Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC) |
Journal | : | Cancer Cell International, 9(1):9 |
Authors | : | Tsui SM, …, Cheng P, et al. |
Year | : | 2009 |
Index | : | 8 |
Title | : | Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest |
Journal | : | Cancer Letters, 277(1):91–100 |
Authors | : | Lam TL, …, Cheng PNM, et al. |
Year | : | 2009 |
Index | : | 9 |
Title | : | Synchronous primary lung cancer and epidermal growth factor receptor mutation |
Journal | : | The Annals of Thoracic Surgery, 90(3):e38–e39 |
Authors | : | Ma ESK, Cheng PNM, et al. |
Year | : | 2010 |
Index | : | 10 |
Title | : | Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis |
Journal | : | Pigment Cell & Melanoma Research, 24(2):366–376 |
Authors | : | Lam TL, …, Cheng PNM, et al. |
Year | : | 2011 |
Index | : | 11 |
Title | : | Deprivation of arginine by recombinant human arginase in prostate cancer cells |
Journal | : | Journal of Hematology & Oncology, 0.220138889 |
Authors | : | Hsueh EC, …, Cheng PNM, et al. |
Year | : | 2012 |
Index | : | 12 |
Title | : | Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma |
Journal | : | Current Cancer Drug Targets, 12(9):1233–1243 |
Authors | : | Chow AKM, …, Cheng PNM, et al. |
Year | : | 2012 |
Index | : | 13 |
Title | Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment | |
Journal | : | Experimental Hematology & Oncology, 2:11 |
Authors | : | Fung KL, et al. |
Year | : | 2013 |
Index | : | 14 |
Title | : | Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg) |
Journal | : | Journal of Neuro-Oncology, 129(3):579–581 |
Authors | : | Choy CT, et al. |
Year | : | 2016 |
Index | : | 15 |
Title | : | Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts |
Journal | : | Respiratory Research, 18:80 |
Authors | : | Lam SK, …, Cheng PNM, et al. |
Year | : | 2017 |
Index | : | 16 |
Title | : | The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100 |
Journal | : | International Journal of Cancer, 142(7):1490–1502 |
Authors | : | De Santo C, …, Cheng P, et al. |
Year | : | 2018 |
Index | : | 17 |
Title | : | Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models |
Journal | : | Oncology Reports, 40(4):1994–2004 |
Authors | : | Lam SK, …, Cheng PNM, et al. |
Year | : | 2018 |
Index | : | 18 |
Title | : | Sensitivity of colorectal cancer to arginine deprivation therapy is shaped by differential expression of urea cycle enzymes |
Journal | : | Scientific Reports, 8(1):12096 |
Authors | : | Alexandrou C, …, Cheng PN, et al. |
Year | : | 2018 |
Index | : | 19 |
Title | : | Macrophage-derived IL1β and TNFα regulate arginine metabolism in neuroblastoma |
Journal | : | Cancer Research, 79(3):611–624 |
Authors | : | Fultang L, …, Cheng PN, et al. |
Year | : | 2019 |
Index | : | 20 |
Title | : | Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma |
Journal | : | Oncogenesis, 8(3):18 |
Authors | : | Lam SK, …, Cheng PNM, et al. |
Year | : | 2019 |
Index | : | 21 |
Title | : | Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer |
Journal | : | Cancer Science, 109(11):3471–3482 |
Authors | : | Xu S, …, Cheng PNM, et al. |
Year | : | 2018 |
Index | : | 22 |
Title | : | Targeting the arginine metabolic brake enhances immunotherapy for leukaemia |
Journal | : | International Journal of Cancer, 145(8):2201–2208 |
Authors | : | Mussai F, …, Cheng P, et al. |
Year | : | 2019 |
Index | : | 23 |
Title | : | Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial-mesenchymal transition |
Journal | : | Scientific Reports, 9(1):12030 |
Authors | : | Xu S, …, Cheng PNM, et al. |
Year | : | 2019 |
Index | : | 24 |
Title | : | Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function |
Journal | : | Immunity, 51(6):1074-1087.e9 |
Authors | : | Lercher A, …, Cheng PN, et al. |
Year | : | 2019 |
Index | : | P1 |
Title | : | A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma |
Journal | : | ASCO Annual Meeting, e13503 |
Authors | : | Yau CC, …, Cheng PN, et al. |
Year | : | 2010 |
Index | : | P2 |
Title | : | Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma |
Journal | : | ASCO Annual Meeting, e15137 |
Authors | : | Yau TC, Cheng PNM, et al. |
Year | : | 2014 |
Index | : | p3 |
Title | : | Pegylated arginase treatment in mesothelioma xenograft models |
Journal | : | ASCO Annual Meeting, e20083 |
Authors | Ho JCM, …, Cheng PNM | |
Year | : | 2016 |
Index | : | P4 |
Title | : | Inhibition of ornithine decarboxylase to facilitate pegylated arginase treatment in lung adenocarcinoma xenograft model |
Journal | : | ASCO Annual Meeting, e23184 |
Authors | : | Ho JCM, …, Cheng PNM |
Year | : | 2016 |
Index | : | P5 |
Title | : | Endogenous arginase 2 as a biomarker for PEGylated arginase 1 treatment in squamous cell lung carcinoma xenograft models |
Journal | : | ASCO Annual Meeting, e20538 |
Authors | : | Ho JCM, …, Cheng PNM, et al. |
Year | : | 2018 |